813 related articles for article (PubMed ID: 27166782)
1. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
Zhou G; Liu Z; Myers JN
J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in head and neck cancer.
Nathan CA; Khandelwal AR; Wolf GT; Rodrigo JP; Mäkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
Mol Carcinog; 2022 Apr; 61(4):385-391. PubMed ID: 35218075
[TBL] [Abstract][Full Text] [Related]
3. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer.
Caponio VCA; Troiano G; Adipietro I; Zhurakivska K; Arena C; Mangieri D; Mascitti M; Cirillo N; Lo Muzio L
Br J Cancer; 2020 Oct; 123(8):1302-1314. PubMed ID: 32684626
[TBL] [Abstract][Full Text] [Related]
4. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
[TBL] [Abstract][Full Text] [Related]
5. Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis.
Wu ES; Park JY; Zeitouni JA; Gomez CR; Reis IM; Zhao W; Kwon D; Lee E; Nelson OL; Lin HY; Franzmann EJ; Savell J; McCaffrey TV; Goodwin WJ; Hu JJ
Head Neck; 2016 Aug; 38(8):1234-41. PubMed ID: 27028310
[TBL] [Abstract][Full Text] [Related]
6. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.
Xie TX; Zhou G; Zhao M; Sano D; Jasser SA; Brennan RG; Myers JN
Laryngoscope; 2013 Jun; 123(6):1416-23. PubMed ID: 23625637
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
[TBL] [Abstract][Full Text] [Related]
8. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
9. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
Poeta ML; Manola J; Goldwasser MA; Forastiere A; Benoit N; Califano JA; Ridge JA; Goodwin J; Kenady D; Saunders J; Westra W; Sidransky D; Koch WM
N Engl J Med; 2007 Dec; 357(25):2552-61. PubMed ID: 18094376
[TBL] [Abstract][Full Text] [Related]
11. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
[TBL] [Abstract][Full Text] [Related]
12. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.
Masica DL; Li S; Douville C; Manola J; Ferris RL; Burtness B; Forastiere AA; Koch WM; Chung CH; Karchin R
Hum Genet; 2015 May; 134(5):497-507. PubMed ID: 25108461
[TBL] [Abstract][Full Text] [Related]
13. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
14. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.
Sandulache VC; Skinner HD; Ow TJ; Zhang A; Xia X; Luchak JM; Wong LJ; Pickering CR; Zhou G; Myers JN
Cancer; 2012 Feb; 118(3):711-21. PubMed ID: 21720999
[TBL] [Abstract][Full Text] [Related]
15. High-risk TP53 mutations predict poor primary treatment response of patients with head and neck squamous cell carcinoma.
Caponio VCA; Zhurakivska K; Mascitti M; Togni L; Spirito F; Cirillo N; Lo Muzio L; Troiano G
Oral Dis; 2024 May; 30(4):2018-2026. PubMed ID: 37501500
[TBL] [Abstract][Full Text] [Related]
16. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
El Baroudi M; Machiels JP; Schmitz S
Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
[TBL] [Abstract][Full Text] [Related]
17. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.
Sano D; Xie TX; Ow TJ; Zhao M; Pickering CR; Zhou G; Sandulache VC; Wheeler DA; Gibbs RA; Caulin C; Myers JN
Clin Cancer Res; 2011 Nov; 17(21):6658-70. PubMed ID: 21903770
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population.
Maruyama H; Yasui T; Ishikawa-Fujiwara T; Morii E; Yamamoto Y; Yoshii T; Takenaka Y; Nakahara S; Todo T; Hongyo T; Inohara H
Cancer Sci; 2014 Apr; 105(4):409-17. PubMed ID: 24521534
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.
Lindenbergh-van der Plas M; Brakenhoff RH; Kuik DJ; Buijze M; Bloemena E; Snijders PJ; Leemans CR; Braakhuis BJ
Clin Cancer Res; 2011 Jun; 17(11):3733-41. PubMed ID: 21467160
[TBL] [Abstract][Full Text] [Related]
20. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
